ZTS
Zoetis Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$75.81
−0.63%Year over year
Reported trailing growth
- Revenue
- +1.4%
- EBITDA
- -4.1%
- EBIT
- +0.0%
- EPS
- +4.5%
- Free cash flow
- +6.6%
- Operating cash flow
- -1.4%
Forward estimates
Based on analyst estimates
- Revenue
- -2.9%
- EBITDA
- +2.7%
- EPS
- +1.8%
Three-year CAGR
- Revenue
- +5.4%
- EBITDA
- +6.6%
- EBIT
- +7.1%
- Net income
- +8.1%
- EPS
- +10.2%
- Free cash flow
- +19.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026